Knobbe/Martens: Intellectual Property Law
Representative Exits

Medical Devices & Procedures

Representative Exits

Long-time firm client ev3 was acquired by Covidien, a leading global provider of healthcare products, for $2.6 billion. Knobbe Martens represented ev3 and its affiliated companies for many years, helping them to develop a robust patent portfolio in the vascular disease market.

Firm client CoreValve was acquired by Medtronic for $700 million plus additional contingent milestone payments. Knobbe Martens served as intellectual property prosecution, diligence, and litigation counsel for CoreValve, the developer of a transcatheter aortic valve replacement.

VNUS Medical Technologies
Firm client VNUS Medical Technologies, a developer of medical devices for minimally invasive treatment of venous reflux disease, was acquired by Covidien for $440 million.

Firm client Visiogen, an ophthalmic start-up developing innovative intraocular lenses, was acquired by Abbott Medical Optics for $400 million. In addition to representing Visiogen in acquisition diligence, Knobbe Martens was involved with building the client's patent portfolio.

C.R. Bard
Knobbe Martens represented firm client C.R. Bard in its acquisition of SenoRx, the developer of minimally invasive devices for the treatment of breast cancer. SenoRx was acquired for about $213 million. The firm conducted extensive target diligence on SenoRx, analyzing over 1200 patents in under 3 weeks in advising C.R. Bard on the transaction. The firm also represented C.R. Bard in performing target due diligence for its acquisition of Medivance, a leader in the field of products for therapeutic hypothermia to treat critically ill patients. Medivance was acquired for $250 million.

Knobbe Martens client EKOS Corporation was acquired by BTG (a British pharmaceutical company) for $180 Million and up to $40 million in additional payouts if milestones are met. EKOS is a medical device company that makes ultrasound catheters that use advanced ultrasound excitation to precondition blood clots for rapid clot removal.  Knobbe Martens has been the sole IP counsel for EKOS since 2002.

Attorney Finder